Liraglutide injection (Victoza)
- BNF:
- 6.1.2.3
- Status:
- Do Not Prescribe (DNP), Red, Green
- Decision Date:
- July 2016
Comments
Prescribe by brand.
Liraglutide (Victoza):
Liraglutide (Saxenda):
- RED: NICE TA664 - Liraglutide (Saxenda) for managing overweight and obesity. Prescribe by brand. Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, but it is restricted to prescribing in secondary care by a specialist multidisciplinary tier 3 weight management service with a commercial agreement in place. (Decision date - January 2021)
- DNP: NICE TA749 – Liraglutide for managing obesity in
people aged 12 to 17 years (terminated appraisal) (Decision date - February 2022)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
search again